Fibrinogen-Like Protein 2 (FGL2) is a Novel Biomarker for Clinical Prediction of Human Breast Cancer

Feng, Yanyan; Guo, Chen; Wang, Hesong; Zhao, Lu; Wang, Wei; Wang, Ting; Feng, Yuyin; Yuan, Kai; Huang, Guangrui

doi:10.12659/msm.923531

Cited by 12 publications

(9 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…FGL2 probably serves as a beneficial marker for the treatment of lung adenocarcinoma. In addition, Feng et al revealed that the expression of FGL2 in breast cancer was also significantly decreased, and the expression of FGL2 was positively correlated with anti-tumor immune cells such as B cells, T cells, macrophages and DC in breast cancer 83 . Strikingly, in another study, it was also verified that the deficiency of FGL2 can accelerate colitis-associated colorectal cancer (CAC) evolution 84 .…”

Section: The Role Of Fgl1 and Fgl2 In Tumorsmentioning

confidence: 99%

The role of Fibrinogen-like proteins in Cancer

Yu¹,

Li²,

Shen³

et al. 2021

Int. J. Biol. Sci.

View full text Add to dashboard Cite

Fibrinogen-associated protein (FREP) family is a family of proteins with a fibrin domain at the carboxyl terminus. Recent investigations illustrated that two members of FREP family, fibrinogen-like protein-1 (FGL1) and fibrinogen-like protein-2 (FGL2), play crucial roles in cancer by regulating the proliferation, invasion, and migration of tumor cells, or regulating the functions of immune cells in tumor microenvironment. Meanwhile, they are potential targets for medical intervention of tumor development. In this review, we discussed the structure, and the roles of FGL1 and FGL2 in tumors, especially the roles in regulating immune cell functions.

show abstract

Section: The Role Of Fgl1 and Fgl2 In Tumorsmentioning

confidence: 99%

The role of Fibrinogen-like proteins in Cancer

Yu¹,

Li²,

Shen³

et al. 2021

Int. J. Biol. Sci.

View full text Add to dashboard Cite

show abstract

“…Among them, 21 genes have been recorded in the DisGeNET [ 38 ] database (v7.0), excluding C9orf68, and 8 risk genes (ANLN [ 39 ], BIRC3 [ 40 ], CD200R1 [ 41 ], CD226 [ 42 ], CLEC10A [ 43 ], PPP2R2B [ 44 ], PTPRC [ 45 ], SPN [ 46 ]) are already reported for BRCA. We also identified 8 other genes (CD79A [ 47 ], EOMES [ 48 ], CAMK4 [ 49 ], FGL2 [ 50 ], KLRB1 [ 51 ], LGALS2 [ 52 ], SLA2 [ 53 ], STAP1 [ 54 ] that have been reported in previous BRCA studies. In addition, three cancer genes (BIRC3, CD79A, and PTPRC) overlapped with the Cancer Gene Census in COSMIC (v97) [ 55 ], further supporting their relevance in the context of cancer, majorly BRCA.…”

Section: Resultsmentioning

confidence: 99%

Differential whole-genome doubling based signatures for improvement on clinical outcomes and drug response in patients with breast cancer

Lv,

Feng,

Yang

et al. 2024

Heliyon

View full text Add to dashboard Cite

“…The low expression level of FGL2 is associated with a poor prognosis in patients with breast cancer. In addition, the expression level of FGL2 is positively correlated with the infiltration of breast cancer cells, especially those with high anti-tumor activity (46). LAT2 promotes the progression of multiple tumors and drug resistance (47,48).…”

Section: Discussionmentioning

confidence: 99%

Identification and Validation of Immune Molecular Subtypes and Immune Landscape Based on Colon Cancer Cohort

Zhang

2022

Front. Med.

View full text Add to dashboard Cite

BackgroundThe incidence and mortality rates of colon adenocarcinoma (COAD), which is the fourth most diagnosed cancer worldwide, are high. A subset of patients with COAD has shown promising responses to immunotherapy. However, the percentage of patients with COAD benefiting from immunotherapy is unclear. Therefore, gaining a better understanding of the immune milieu of colon cancer could aid in the development of immunotherapy and suitable combination strategies.MethodsIn this study, gene expression profiles and clinical follow-up data were downloaded from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases, and molecular subtypes were identified using the ConsensusClusterPlus package in R. Univariate and multivariate Cox regression analyses were performed to evaluate the prognostic value of immune subtypes. The graph structure learning method was used to reduce the dimension to reveal the internal structure of the immune system. Weighted correlation network analysis (WGCNA) was performed to identify immune-related gene modules. Finally, western blotting was performed to verify the gene expression patterns in COAD samples.ResultsThe results showed that 424 COAD samples could be divided into three subtypes based on 1921 immune cell-related genes, with significant differences in prognosis between subtypes. Furthermore, immune-related genes could be divided into five functional modules, each with a different distribution pattern of immune subtypes. Immune subtypes and gene modules were highly reproducible across many data sets. There were significant differences in the distribution of immune checkpoints, molecular markers, and immune characteristics among immune subtypes. Four core genes, namely, CD2, FGL2, LAT2, and SLAMF1, with prognostic significance were identified by WGCNA and univariate Cox analysis.ConclusionOverall, this study provides a conceptual framework for understanding the tumor immune microenvironment of colon cancer.

show abstract

Fibrinogen-Like Protein 2 (FGL2) is a Novel Biomarker for Clinical Prediction of Human Breast Cancer

Cited by 12 publications

References 26 publications

The role of Fibrinogen-like proteins in Cancer

The role of Fibrinogen-like proteins in Cancer

Differential whole-genome doubling based signatures for improvement on clinical outcomes and drug response in patients with breast cancer

Identification and Validation of Immune Molecular Subtypes and Immune Landscape Based on Colon Cancer Cohort

Contact Info

Product

Resources

About